Latest Ratios: P/E Ratio -1.1x · EV/EBITDA N/A · ROE -8145.2%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $24M | $19M | $37M | $116M | $21M | $42M | $58M | $69M | $106M | — | — |
| Enterprise Value | $21M | $17M | $33M | $112M | $39M | $55M | $64M | $68M | $99M | — | — |
| P/E Ratio → | -1.14 | — | — | 21.83 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 658.37 | 36.69 | 42.53 | 12.10 | 1076.81 | 39.86 | 75.94 | — | — |
| P/B Ratio | — | — | 72.58 | — | — | — | — | 26.32 | 12.88 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 597.58 | 35.37 | 77.49 | 15.75 | 1183.64 | 39.63 | 71.14 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | 19.14 | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | -246.4% | 97.1% | 100.0% | -9.6% | -2272.2% | 42.2% | 39.8% | 51.2% | 45.3% |
| Operating Margin | — | — | -30442.9% | -99.2% | -454.1% | -47.1% | -19272.2% | -726.8% | -748.2% | -599.5% | -764.6% |
| Net Profit Margin | — | — | -19894.6% | 167.1% | -536.4% | -36.5% | -20120.4% | -703.4% | -537.4% | -468.7% | -929.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -8145.2% | -8145.2% | -2193.1% | — | — | — | — | -224.1% | -90.7% | -79.1% | — |
| ROA | -280.5% | -280.5% | -142.0% | 86.3% | -83.9% | -35.7% | -191.2% | -134.2% | -73.9% | -102.4% | -480.7% |
| ROIC | — | — | — | — | -375.5% | -219.3% | -601.8% | -503.0% | -634.8% | — | — |
| ROCE | -620.2% | -620.2% | -286.2% | -871.6% | — | — | -767.2% | -203.0% | -126.2% | -101.2% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.53 | — | — | — | — | 0.75 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -6.70 | — | — | — | — | -0.15 | -0.81 | -0.89 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -89.13 | -89.13 | -20.31 | 10.44 | -167.92 | -407.76 | -24.74 | — | — | -701.42 | -509.56 |
Net cash position: cash ($3M) exceeds total debt ($196000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.71 | 1.71 | 2.40 | 5.39 | 0.24 | 0.25 | 0.43 | 1.23 | 3.22 | 5.79 | 0.03 |
| Quick Ratio | 1.71 | 1.71 | 2.40 | 5.39 | 0.24 | 0.25 | 0.43 | 1.23 | 3.22 | 5.79 | 0.03 |
| Cash Ratio | 0.86 | 0.86 | 1.55 | 5.39 | 0.06 | 0.07 | 0.10 | 0.71 | 2.75 | 5.62 | 0.01 |
| Asset Turnover | — | — | 0.01 | 0.35 | 0.15 | 1.10 | 0.01 | 0.23 | 0.13 | 0.15 | 0.52 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | 2.92 | 2.63 | 2203.52 | 76.68 | 34.25 | 27.82 | 67.48 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | 4.6% | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $10M | $7M | $8M | $1M | $1M | $1M | $1M | $992721 | $1M | $1M |
Imminent liquidity and dilution
As reported in recent financial statements, Serina Therapeutics' ROIC of -95.0% in 2025Q4 highlights a severe inability to generate returns on invested capital, a trend that appears consistent with the firm's pre-revenue status and heavy reliance on external funding to sustain its ongoing clinical research initiatives.
The negative ROIC trend suggests that the company is currently destroying shareholder value through its R&D-heavy cost structure rather than compounding it. Investors should monitor whether future clinical milestones can shift this trajectory, as the current efficiency metrics indicate a business model that is structurally dependent on continuous capital injections.
Based on 2026Q1 data, the company reports a current ratio of 4.18, yet this figure appears misleading when compared to the absolute cash balance of $3.056 million, which suggests that the firm's liquidity buffer is insufficient to support long-term clinical development without immediate and significant external financing.
While the current ratio might suggest a comfortable cushion, the underlying cash position is critically low relative to the company's historical burn rate. This discrepancy warrants further investigation into the composition of current assets, as the lack of liquid capital may force management into dilutive equity offerings sooner than the headline ratios imply.
According to historical filings, the company's DPO has fluctuated significantly, reaching 11,895 days in 2026Q1, which suggests that the firm is managing its cash outflows by aggressively extending payment terms to vendors, a strategy that may indicate underlying pressure on its available working capital resources.
The extreme volatility in DPO and the absence of meaningful asset turnover suggest that the company lacks a stable operational cycle. This inefficiency is typical of pre-revenue entities, but it implies that the firm's ability to manage its supplier relationships is highly sensitive to its limited cash reserves.
As indicated by the negative P/E of -0.97, traditional valuation multiples are fundamentally misapplied to Serina Therapeutics, as they fail to account for the binary nature of clinical-stage biotechnology assets where value is derived from platform optionality rather than current earnings or historical cash flow generation.
Investors should instead focus on metrics like 'cash runway' and 'platform valuation' relative to peers, as P/E and EV/EBITDA ratios obscure the true risk-reward profile of the POZ technology. Relying on standard valuation multiples in this context may lead to an inaccurate assessment of the company's potential for future clinical success.
Includes 30+ ratios · 10 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SER stock.
Serina Therapeutics, Inc.'s current P/E ratio is -1.1x. The historical average is 21.8x.
Serina Therapeutics, Inc.'s return on equity (ROE) is -8145.2%. The historical average is -131.3%.
Based on historical data, Serina Therapeutics, Inc. is trading at a P/E of -1.1x. Compare with industry peers and growth rates for a complete picture.